Abstract
Background: The caprazamycin derivative, CPZEN-45 has previously demonstrated antitubercular activity against Mycobacterium tuberculosis H37Rv. Here, the authors report a basic biopharmaceutical characterization of the compound focusing on in vitro permeability and cytotoxicity, with respect to the suitability of CPZEN-45 hydrochloride for inhalation treatment of tuberculosis. Results: MTT assays confirmed that CPZEN-45 HCl had no acute cytotoxic effects up to 3 mg/ml. In transport studies, apparent permeability coefficients of CPZEN-45 HCl across Calu-3 monolayers in absorptive and secretive directions were 0.43 ± 0.20 × 10-6 cm/s and 0.38 ± 0.12 × 10-6 cm/s, respectively. Across ATI-like monolayers, apparent permeability values were 12.10 ± 4.31 × 10-6 cm/s and 8.50 ± 1.83 × 10-6 cm/s. CPZEN-45 HCl formed colloidal complexes at concentrations above 0.38 mg/ml; however, these complexes were not micelles, as assessed by Orange OT encapsulation assay. Conclusion: CPZEN-45 is an interesting new drug candidate with potential to be used in aerosol therapy of tuberculosis.
Financial & competing interests disclosure
The authors acknowledge funding by a Strategic Research Cluster grant (07/SRC/B1154) under the National Development Plan co-funded by EU Structural Funds and Science Foundation Ireland. The authors greatly appreciate the donation and supply of compounds by the Institute of Medicinal Chemistry (IMC) and Meiji Company, Japan.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.